Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

An accelerated pathway for targeted cancer therapies

Nature Reviews Drug Discovery volume 10, pages 79–80 (2011)Cite this article

Subjects

Abstract

A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. US FDA. Drug–Diagnostic Co-Development Concept Paper. FDA website [online], (2005).

  2. Mandrekar, S. J. & Sargent, D. J. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27, 4027–4034 (2009).

    Article  Google Scholar 

  3. Hoering, A. et al. Randomized phase III clinical trial designs for targeted agents. Clin. Cancer Res. 14, 4358–4367 (2008).

    Article  CAS  Google Scholar 

  4. Simon, R. & Maitournam, A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin. Cancer Res. 10, 6759–6763 (2004).

    Article  CAS  Google Scholar 

  5. Jiang, W. et al. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl Cancer Inst. 99, 1036–1043 (2007).

    Article  Google Scholar 

  6. Barker, A.D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97–100 (2009).

    Article  CAS  Google Scholar 

  7. Goodsaid, F. M. et al. Strategic paths for biomarker qualification. Toxicology 245, 219–223 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

P. Keegan of the US FDA provided comments on a draft. E. Karnes, M. Morrison, R. Anderson and E. Khoong of the Brookings Institution, and L. Fahey McGrath of Novartis, contributed to background research and assisted in drafting. The recommendations are based on a discussion at the Conference on Cancer Clinical Research, 14 September 2009, hosted by the Brookings Institution and Friends of Cancer Research.

Author information

Authors and Affiliations

  1. Mark McClellan and Joshua Benner are at the Engelberg Center for Health Care Reform, Brookings Institution, Washington DC, USA.,

    Mark McClellan & Joshua Benner

  2. Richard Schilsky is at the University of Chicago Medical Center, Chicago, Illinois, USA.,

    Richard Schilsky

  3. David Epstein is at Novartis Pharmaceuticals, Basel, Switzerland.,

    David Epstein

  4. Ray Woosley is at the Critical Path Institute, Tucson, Arizona, USA.,

    Ray Woosley

  5. Stephen Friend is at Sage Bionetworks, Seattle, Washington, USA.,

    Stephen Friend

  6. David Sidransky is at Johns Hopkins University, Baltimore, Maryland, USA.,

    David Sidransky

  7. Cindy Geoghegan is at Patient and Partners LLC, New York City, New York, USA.,

    Cindy Geoghegan

  8. David Kessler is at the University of California in San Francisco, San Francisco, California, USA.,

    David Kessler

Authors
  1. Mark McClellan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua Benner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Schilsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ray Woosley
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen Friend
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David Sidransky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cindy Geoghegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David Kessler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joshua Benner.

Ethics declarations

Competing interests

David Epstein is CEO of novartis Oncology. Richard Schilsky has served on the scientific advisory board of Foundation medicine. Joshua Benner, Cindy Geoghegan, Stephen Friend, David Kessler, Mark McClellan, David Sidransky and Ray Woosley declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McClellan, M., Benner, J., Schilsky, R. et al. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov 10, 79–80 (2011). https://doi.org/10.1038/nrd3360

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3360

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research